-
Trastuzumab emtansine, sold
under the
brand name
Kadcyla, is an antibody-drug
conjugate consisting of the
humanized monoclonal antibody trastuzumab (Herceptin)...
-
called "emtansine" in its INN name
trastuzumab emtansine,
marketed as
Kadcyla DM1
attached to an
antibody with ImmunoGen's SPP
linker is
called "mertansine"...
- with
previously untreated HER2-positive
metastatic breast cancer. 2013:
Kadcyla (ado-trastuzumab emtansine): The
first Genentech antibody-drug conjugate...
-
Trastuzumab emtansine (ado-trastuzumab
emtansine or T-DM1,
trade name:
Kadcyla,
marketed by
Genentech and Roche) was
approved in
February 2013 for the...
-
receptor monoclonal antibody for
rheumatoid arthritis 2014:
Launch of
Kadcyla , a
cancer drug,
Chugai Pharma China Co Ltd.
founded 2015 – In
March the...
-
Eribulin was
approved in the US in Nov 2010. A
targeted therapy drug,
Kadcyla, was
approved in
February 2013. This antibody-drug
conjugate targets only...
-
congestive heart failure.
Invirase (saquinavir), for HIV-1 infection.
Kadcyla (trastuzumab emtansine), for HER-2
positive breast cancer.
Klonopin Rivotril...
-
promising anticancer drugs" (PDF).
Cancer Res. 52 (1): 127–31. PMID 1727373. "
Kadcyla EPAR".
European Medicines Agency (EMA). 17
September 2018. "Drug Approval...
-
Ulcerative colitis Plaque psoriasis 761024 Link ado-trastuzumab
emtansine Kadcyla Genentech 2/22/2013
intravenous humanized, antibody-drug
conjugate HER2...
-
Institute for
Health and Care
Excellence appraisal committee in
respect of
Kadcyla on the
basis that it
should have
considered that
under the scheme, the...
